Recombinant major inner capsid protein (VP6) of the IDIR strain of group B rotavirus (GBR) was incorporated in a solid-phase immunoassay to access antibody response to infection in humans. Expression of VP6 in insect cells permitted design of a highly sensitive assay that avoided the contaminants present in GBR antigens obtained from fecal specimens. Among patients infected with the ADRV strain of GBR in China, increased reactivity with recombinant VP6 was observed in convalescent-phase sera in comparison with sera obtained shortly after infection (P = 0.0084). Anti-VP6 antibodies were detectable as soon as 7 days after onset of gastrointestinal symptoms, and serum reactivity persisted in specimens drawn more than 1 year after infection. Solid-phase immunoassay with recombinant VP6 was next employed in order to assess anti-GBR antibody in 513 serum specimens obtained from 423 Maryland residents (ages, 7 
individuals (<1%) exhibited serum antibodies directed against the recombinant VP6 (ages, 54 to 95 years; mean age, 77 years). Examination of 129 additional serum specimens including some from other geographic regions of the United States failed to reveal the presence of anti-GBR antibody. Anti-GBR antibody was also not detected in any of 131 serum specimens from 60 staf and residents of a nursing home in Switzerland. While infection of humans with GBR has been uncommon in these locations outside of China, the detection of serum antibodies in older individuals in the United States either indicated an unknown, age-related risk factor or may have indicated infection in the more distant past. The availability of these reagents should allow surveys for GBR infection among additional populations that have not previously been investigated.
Group B rotaviruses (GBR) have been associated with large outbreaks of gastroenteritis in China, with attack rates ranging from 5 to 51% (3, 8, 9, 11, 14, 15, 19) . Gastroenteritis was initially reported among adults, and the infecting GBR strain was termed ADRV (adult diarrhea rotavirus). However, infection among all age groups has subsequently been noted, including at least one outbreak in a newborn nursery (3) . Illness has been characterized by vomiting, abdominal cramps, and severe watery diarrhea without blood. Fever has not been commonly noted, and the mortality rate has generally been low. Blocking immunoassays with fecal isolates of GBR have clearly detected rises in antibody titer following ADRV infection in Chinese patients, but the peak titers have generally been much lower than after infection with group A rotavirus (GAR) (7, 10, (13) (14) (15) . Counterimmunoelectrophoresis with fecal GBR antigens has indicated anti-ADRV antibody in 12 to 41% of serum samples from various locations in China (11) .
Despite ing 10 serum samples) from each country was positive (14) . Among 110 veterinarians and farm workers and 100 blood donors in the United Kingdom, Brown and coworkers found blocking antibody to ADRV in 4 and 10% of specimens, respectively (2) .
The ability to conduct more extensive seroepidemiologic investigations in additional locations would greatly aid in defining the spectrum of GBR infection. However, evaluations have been restricted because GBR have not grown well in tissue culture, antigenic reagents obtained from fecal specimens have been limited, and these reagents have been difficult to purify (6, 16, 18) . In order to devise more convenient and useful detection of anti-GBR antibody, we have recently developed GBR reagents from alternate sources, based on the IDIR agent (infectious diarrhea of infant rats) originally isolated in Baltimore (12, 17) . This virus was first identified in a colony of laboratory rats, but infection of a small number of humans with the IDIR agent has also been documented in Maryland (5) . Cloning of gene 6 of the IDIR agent and expression of the gene in a baculovirus recombinant resulted in large-scale synthesis of GBR major inner capsid protein (4, 12) . In previous studies, this recombinant VP6 was specifically recognized by antisera directed against heterologous GBR strains obtained from a variety of mammalian species (12 (8) .
One uninfected individual served as a negative control.
The reactivities of the sera with recombinant VP6 varied with the time of collection. Uninfected control sera and all five specimens obtained within 6 days of the onset of illness failed to react with VP6 in the solid-phase immunoassay (Fig. 1 ).
Anti-VP6 antibody was noted in serum obtained from a single patient 7 days after the onset of symptoms, but the first specimens obtained at postinfection days 15 and 23 from two other patients failed to react with the recombinant protein (Fig. 1) antibody reactivity between first and second specimens was noted, but the first specimen from that patient was not obtained until 31 days after the onset of gastroenteritis.
Serial dilutions of sera from ADRV-infected patients were also evaluated for reactivity with GBR VP6 in the solid-phase immunoassay. Fifteen serum samples were initially reactive at a dilution of 1:100 (Table 1) . Anti-VP6 antibodies were still detected at 1:500 dilutions for eight of these specimens. Reactivity with GBR VP6 was detectable in one specimen even after a 1:12,500 dilution. That specimen was obtained approximately 2 weeks after acute infection and demonstrated the most reactivity of any of the sera tested at 1:100 dilution.
The results of the solid-phase immunoassay were subsequently compared with reactivity in an immunoblot format. Serum samples were initially tested at the same concentration employed for screening in the solid-phase immunoassay (1:100 dilution). However, at that concentration reactions with other cellular and baculovirus proteins prevented assessment of reactivity with recombinant VP6 and necessitated the use of more-dilute serum specimens. At dilutions of 1:1,000, an intense signal was visible in the immunoblot format with two serum samples that had previously exhibited among the highest reactivities in the solid-phase immunoassay. Reaction was not detected with 1:1,000 dilutions of sera which had exhibited lower reactivity in the solid-phase immunoassay. No reactivity was observed with acute-phase sera or sera from an uninfected individual.
Of note, post-infectious-phase serum specimens from five (Fig. 1 ). These findings demonstrated persistent serum reactivity with recombinant GBR VP6 for extended periods after infection and indicated that the assay would be useful for epidemiologic studies. Assessment of sera at later times after acute infection might provide additional data about persistence of anti-GBR antibodies, but this was not done. Such evaluations would be valuable, since a decrease in antibody titers over time could potentially lead to an underestimate of human exposure to GBR. The reactivities of 379 random serum specimens from 331 Maryland residents were tested by solid-phase immunoassay with recombinant GBR VP6. Serum samples were obtained from the laboratories of the Department of Health and Mental Hygiene from among samples submitted for evaluation of antibodies directed against a wide variety of pathogens. Aliquots of these sera were coded and then evaluated for antibody directed against GBR. Tests for anti-GBR antibody were also conducted on an additional 134 serum samples obtained from 92 patients in five Maryland nursing homes following investigations of respiratory or gastrointestinal disease. Initial evaluations had failed to identify a specific causative agent in the nursing home outbreaks. These 423 individuals ranged in age from 7 months to 96 years, with a mean age of 47 years. Fifty-nine percent of the individuals were female.
Five specimens from four Maryland residents were reactive with recombinant GBR VP6 in the solid-phase immunoassay in which sera were tested at dilutions of 1:100 ( The low prevalence of serum reactivity against recombinant GBR VP6 in the current study was consistent with the results of earlier surveys which employed ADRV reagents prepared from fecal specimens (13, 14) . While these studies have indicated marked differences between GBR exposure in China and other geographic regions, a number of questions concerning the epidemiology of GBR infection remain unanswered. Why GBR should be so common in China and not in other areas is puzzling. Transmission of GBR can apparently occur through infected water supplies as well as through person-toperson contact (8, 10) . Differences in the handling of drinking water and waste disposal might account for variation in the prevalence of human infection with GBR. However, travel of ill persons could still allow dissemination of GBR by personto-person spread. There is no apparent reason to believe that person-to-person transmission to other areas could not occur in the future.
The detection of anti-GBR antibody in four patients from Maryland indicated that exposure to GBR had occurred in a small portion of the population (<1%). Serum from one of the patients was obtained during the course of an investigation of a diarrhea outbreak at a nursing home, but the reactivities in acute-phase and convalescent-phase specimens indicated that GBR was not the cause of disease in that case. While the seropositive Maryland residents may have been exposed to GBR during travel outside the state, this information could not be obtained as part of the current study. More likely, the presence of anti-GBR antibody in these cases represented exposure to a virus endemic to the local geographic region. A small outbreak of human infection with the IDIR strain of GBR has previously been documented in Baltimore (5). Recurrences of this type of exposure remain possible, since the urban rat population in Baltimore remains a focus for this infection (3a 
